Our Services
Medical Information
Helpful Resources
Published on: 5/22/2026
Biologics such as dupilumab, mepolizumab, benralizumab, and omalizumab precisely block key immune signals (IL-4, IL-5, IL-13, or IgE) to reduce inflammation, shrink sinus polyps, and improve breathing without surgery. These targeted therapies minimize systemic steroid use, lower recurrence rates, and offer a sustainable, noninvasive alternative to endoscopic procedures.
There are several important considerations—from choosing the right biologic and dosing schedule to understanding potential side effects and insurance access—that could impact your next steps. See complete details below.
Chronic rhinosinusitis with nasal polyps (CRSwNP) affects up to 4% of adults. Nasal polyps are noncancerous swellings of the sinus lining that can block airflow, cause congestion, reduce smell and taste, and lead to repeated infections. Until recently, surgery and steroids were the mainstays of treatment. Now, biologics offer a non-surgical option, targeting the immune drivers of polyp formation at a molecular level.
If you're wondering whether your symptoms point to sinusitis or nasal polyps, Ubie's free AI-powered symptom checker can help you understand what might be causing your discomfort in just a few minutes.
While surgery can remove polyps, they often recur. Corticosteroids reduce inflammation but can cause side effects with long-term use.
Sinus polyps form when chronic inflammation in the nose and sinuses triggers overgrowth of the mucous-lining tissue. Key players include:
Type 2 Inflammation
Eosinophils
IgE Antibodies
Mucus Overproduction
By interrupting these pathways, biologics can reduce inflammation, shrink existing polyps, and prevent new ones from forming—without the need for surgery.
Biologics that shrink sinus polyps without surgery focus on molecules central to Type 2 inflammation.
Blocking Cytokines
Preventing Cell Recruitment
Reducing Mucus and Swelling
Altering the Local Immune Environment
By precisely targeting these steps, biologics effectively shrink polyps and control symptoms over the long term.
Advantages of choosing biologics that shrink sinus polyps without surgery include:
No treatment is without risks. Common side effects of biologics may include:
Rare but serious events can occur. Always report new or severe symptoms to your healthcare provider.
Discuss Options with Your Doctor
Insurance and Access
Monitor Progress
Lifestyle and Support
If you're unsure whether your sinus issues are related to polyps or simple sinusitis, Ubie's free symptom checker can provide personalized insights based on your specific symptoms.
Biologics represent a major advance in treating chronic sinus polyps without resorting to repeated surgeries. By targeting the molecular drivers of inflammation—IL-4, IL-5, IL-13, and IgE—they offer precise, effective, and long-lasting relief.
Always speak to a doctor about any symptoms that could be serious or life-threatening. Your healthcare provider can help determine if biologic therapy is right for you and guide you through treatment safely.
(References)
* Katsarolis I, Psaroulis K, Papadopoulos S, Georgakopoulos D, Tsolia M, Georgalas C. Molecular Mechanisms of Biologics in Chronic Rhinosinusitis With Nasal Polyps. J Clin Med. 2024 Mar 8;13(6):1460. doi: 10.3390/jcm13061460. PMID: 38541249.
* Liu Z, Wu Y, Lin S, Lin Z, Zhang J, Li K, Li Z, Huang C. Understanding the Molecular Mechanisms and Therapeutic Targets for Biologic Therapy in Chronic Rhinosinusitis With Nasal Polyps: A Comprehensive Review. Front Immunol. 2022 Jul 25;13:935105. doi: 10.3389/fimmu.2022.935105. PMID: 35949508.
* Brescia G, D'Amato M, D'Amato F, Calabrese C, D'Amato L, D'Amato G. Biologic Treatment in Chronic Rhinosinusitis with Nasal Polyps: Molecular Mechanisms and Efficacy. J Clin Med. 2023 Dec 27;13(1):153. doi: 10.3390/jcm13010153. PMID: 38200676.
* Al-Shaikh T, Abdo T, Al-Tawil H, Al-Shorbagy M. Dupilumab, omalizumab, and mepolizumab in chronic rhinosinusitis with nasal polyps: from molecular mechanisms to clinical efficacy. Allergy Asthma Clin Immunol. 2023 Jun 13;19(1):47. doi: 10.1186/s13223-023-00796-7. PMID: 37311956.
* Wang H, Zhou Y, Yang S. Type 2 inflammation and biologics in chronic rhinosinusitis with nasal polyps: A systematic review. Int J Clin Pract. 2022 Mar;76(3):e15017. doi: 10.1111/ijcp.15017. Epub 2021 Nov 16. PMID: 34783362.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.